Exploring the Impact of Head Group Modifications on the Anticancer Activities of Fatty-Acid-like Platinum(IV) Prodrugs: A Structure-Activity Relationship Study.
anticancer
platinum(IV) prodrugs
structure–activity relationship
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
27 Aug 2023
27 Aug 2023
Historique:
received:
30
07
2023
revised:
18
08
2023
accepted:
23
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
We conducted the first comprehensive investigation on the impact of head group modifications on the anticancer activities of fatty-acid-like Pt(IV) prodrugs (FALPs), which are a class of platinum-based metallodrugs that target mitochondria. We created a small library of FALPs (
Identifiants
pubmed: 37686109
pii: ijms241713301
doi: 10.3390/ijms241713301
pmc: PMC10487970
pii:
doi:
Substances chimiques
Prodrugs
0
Fatty Acids
0
Platinum
49DFR088MY
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NCI NIH HHS
ID : R15 CA249712
Pays : United States
Références
J Med Chem. 2012 Sep 13;55(17):7571-82
pubmed: 22876932
Eur J Med Chem. 2022 Dec 5;243:114680
pubmed: 36152386
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Chem Soc Rev. 2022 Jul 4;51(13):5518-5556
pubmed: 35699475
Eur J Med Chem. 2019 Jan 1;161:310-322
pubmed: 30368130
J Am Chem Soc. 2015 Dec 2;137(47):14854-7
pubmed: 26561720
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
Int J Mol Sci. 2021 Jul 31;22(15):
pubmed: 34361037
Adv Mater. 2019 Apr;31(14):e1805888
pubmed: 30762908
RSC Adv. 2019 Jul 2;9(36):20513-20517
pubmed: 35515556
J Am Chem Soc. 2014 Jun 18;136(24):8790-8
pubmed: 24902769
Chemistry. 2018 May 2;24(25):6606-6616
pubmed: 29655185
Chem Commun (Camb). 2020 Sep 28;56(76):11271-11274
pubmed: 32830841
Dalton Trans. 2022 Jul 26;51(29):10835-10846
pubmed: 35781551
Curr Opin Chem Biol. 2023 Feb;72:102235
pubmed: 36516614
J Med Chem. 2017 Jul 13;60(13):5736-5748
pubmed: 28603992
Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92
pubmed: 22773807
Chem Commun (Camb). 2020 Sep 15;56(73):10706-10709
pubmed: 32789350
Chem Sci. 2020 Nov 12;11(48):12888-12917
pubmed: 34123239
Theranostics. 2022 Feb 7;12(5):2115-2132
pubmed: 35265202
J Med Chem. 2019 May 23;62(10):5176-5190
pubmed: 31030506
Dalton Trans. 2022 Feb 1;51(5):2012-2018
pubmed: 35029256
Front Pharmacol. 2022 Oct 17;13:1035217
pubmed: 36324675
Dalton Trans. 2018 Jul 31;47(30):9934-9974
pubmed: 29904760
Adv Healthc Mater. 2023 Sep;12(22):e2300253
pubmed: 37097737
Chem Rev. 2016 Mar 9;116(5):3436-86
pubmed: 26865551
Nat Med. 2009 Sep;15(9):1010-2
pubmed: 19734877
Curr Opin Chem Biol. 2023 Feb;72:102236
pubmed: 36516491
Front Physiol. 2019 Jan 11;9:1898
pubmed: 30687116
J Am Chem Soc. 2022 Oct 12;144(40):18532-18544
pubmed: 36178375
J Med Chem. 2016 Oct 13;59(19):9035-9046
pubmed: 27603506
ACS Nano. 2020 Dec 22;14(12):16984-16996
pubmed: 33283501
Metallomics. 2009;1(4):280-91
pubmed: 20046924
RSC Adv. 2023 Jun 1;13(24):16488-16511
pubmed: 37274408
Curr Opin Chem Biol. 2023 Apr;73:102276
pubmed: 36878171
Nat Rev Cancer. 2007 Aug;7(8):573-84
pubmed: 17625587
Molecules. 2022 Dec 29;28(1):
pubmed: 36615466
Curr Opin Chem Biol. 2023 Jun;74:102290
pubmed: 36989943
J Am Chem Soc. 2023 Jun 21;145(24):12998-13002
pubmed: 37283248
Nat Rev Drug Discov. 2005 Apr;4(4):307-20
pubmed: 15789122
Chem Rev. 1999 Sep 8;99(9):2467-98
pubmed: 11749487
Anticancer Res. 2015 May;35(5):2783-94
pubmed: 25964558
Int J Mol Sci. 2023 Jan 25;24(3):
pubmed: 36768690
Curr Opin Chem Biol. 2023 Feb;72:102237
pubmed: 36542889
Angew Chem Int Ed Engl. 2022 Oct 4;61(40):e202205900
pubmed: 35781763
Nat Commun. 2015 Oct 27;6:8692
pubmed: 26503691
Angew Chem Int Ed Engl. 2019 Oct 1;58(40):14224-14228
pubmed: 31389144
J Mater Chem B. 2023 Aug 15;:
pubmed: 37581251
J Inorg Biochem. 2021 Apr;217:111353
pubmed: 33477089
Curr Opin Chem Biol. 2023 Jun;74:102303
pubmed: 37075513